Full text
Earnings transcript
Read the complete earnings call transcript.
EHC
Encompass Health Corporation
$104.19
3.08
(3.05%)
| Exchange: | NYSE |
| Market Cap: | 10.336B |
| Shares Outstanding: | 28.452M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Care Facilities | |||||
| CEO: | Mark J. Tarr | |||||
| Full Time Employees: | 28572 | |||||
| Address: |
| |||||
| Website: | https://www.encompasshealth.com |
Encompass Health Corporation delivers a range of post-acute healthcare services across the United States, offered both in dedicated facilities and directly within patients’ homes. The company’s operations are divided into two primary divisions: Inpatient Rehabilitation, and Home Health and Hospice. Its Inpatient Rehabilitation division specializes in providing focused recovery treatment, available on an inpatient or outpatient basis. This care is designed for individuals recuperating from significant health challenges such as strokes, neurological disorders, cardiac and pulmonary issues, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment primarily serves the Southeast and Texas regions. Within this segment, home health services encompass a variety of Medicare-certified care options for adult patients, including skilled nursing, medical social work, home health aide assistance, and various therapies like physical, occupational, and speech therapy. Hospice services, on the other hand, provide in-home comfort and support for terminally ill patients and their families. As of June 1, 2022, Encompass Health maintained a substantial network, managing 149 hospitals, 252 home health locations, and 99 hospice locations spread across 42 U.S. states and Puerto Rico. The company, which established its roots in 1983 and is headquartered in Birmingham, Alabama, was formerly known as HealthSouth Corporation until its name change to Encompass Health Corporation in January 2018.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 4,801,200 | 5,373,200 | 5,935,200 |
| Gross Profit | 1,982,800 | 2,233,200 | 5,680,800 |
| EBITDA | 1,005,700 | 1,186,600 | 1,404,100 |
| Operating Income | 1,724,800 | 864,500 | 1,053,100 |
| Net Income | 352,000 | 455,700 | 566,200 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 6,102,400 | 6,534,700 | 7,089,700 |
| Total Liabilities | 3,805,200 | 3,685,500 | 3,813,900 |
| Total Stockholders Equity | 1,647,500 | 2,067,000 | 3,217,500 |
| Total Debt | 2,932,800 | 2,713,800 | 266,700 |
| Cash and Cash Equivalents | 69,100 | 85,400 | 72,200 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 850,800 | 1,002,800 | -1,400 |
| Capital Expenditure | -583,100 | -642,500 | -736,400 |
| Free Cash Flow | 267,700 | 360,300 | -737,800 |
| Net Income | 361,600 | 599,400 | 759,100 |
| Net Change in Cash | 50,800 | 18,900 | -20,200 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 8,904,046.658 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 8,967,617.880 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 8,934,700 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 1,938,169.693 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 1,952,007.426 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 1,944,842.095 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 934,011.941 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 942,689.743 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 938,196.009 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 1,394,431.934 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 1,404,387.603 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 1,399,232.448 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 9.180 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 9.220 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 9.140 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: EHC has demonstrated strong revenue growth, as evidenced by consistent increases in revenue and net income over recent periods in the income statements. Key metrics such as high gross profit margin (grossProfitMarginTTM) and net profit margin (netProfitMarginTTM) indicate efficient operations and profitability compared to industry benchmarks.
- Solid Cash Flow Generation: The cash flow statements highlight strong free cash flow (freeCashFlow) and operating cash flow (operatingCashFlow), supported by prudent capital expenditure (capitalExpenditure). This financial flexibility allows EHC to fund innovation and strategic investments without over-reliance on external financing.
- Market Position and Stability: With a competitive market cap (mktCap) and a beta (beta) indicating lower volatility relative to the market, EHC holds a stable position within its sector (sectorName). Strong performance metrics over 1-year and 5-year periods (perf1y, perf5y) further underscore its resilience compared to industry averages (industry_perf1y, industry_perf5y).
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates EHC intrinsic value between $51.87 – $87.66 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about EHC valuation
Is Encompass Health Corporation (EHC) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Encompass Health Corporation (EHC) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is EHC a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether EHC trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is EHC’s P/E ratio?
You can see EHC’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for EHC?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is EHC a good long-term investment?
Whether EHC fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
EHC
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
3.05
Trading Metrics:
| Open: | 102.56 | Previous Close: | 101.11 | |
| Day Low: | 102.26 | Day High: | 104.61 | |
| Year Low: | 92.77 | Year High: | 127.99 | |
| Price Avg 50: | 104.05 | Price Avg 200: | 110.38 | |
| Volume: | 756195 | Average Volume: | 937487 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeEHC full analysis
Welcome to MARKETSNAP’s SWOT analysis for Encompass Health Corporation, or EHC as you might see it ticker-wise. If you’re not familiar with this name, let me give you the quick rundown. Encompass Health is a major player in the healthcare services space, specifically focusing on rehabilitation hospitals and home health services. They operate in a critical niche within the broader healthcare sector, providing post-acute care to patients recovering from serious conditions. With a solid footprint across the U.S., they’ve built…
